Embr Labs, Hygieia, Pluto Biosciences
Embr Labs Raises $35M in Debt Financing
Embr Labs, Inc., a Boston, MA-based maker of Embr Wave, a wearable to treat the symptoms of menopause, raised $35m via intellectual property (IP)-based debt financing.
The round was led by GT Investment Partners in collaboration with Aon plc (NYSE: AON).
The company intends to use the funds to accelerate consumer growth strategy via retail and geographic expansion.
Led by Elizabeth Gazda, CEO, Embr provided the Embr Wave® wristband, using the company’s patented technology, delivers precisely calibrated cooling or warming sensations at the touch of a button for instant, discrete control over hot flashes and related menopause symptoms.
Embr Labs Raises $35M in Debt Financing
Embr Labs, Inc., a Boston, MA-based maker of Embr Wave, a wearable to treat the symptoms of menopause, raised $35m via intellectual property (IP)-based debt financing
College mental health startup Uwill raises $30M
Uwill, a mental health platform for colleges and students, completed a $30 million Series A funding round led by Education Growth Partners.
The company partners with colleges to offer students on-demand virtual access to licensed therapists and providers trained in crisis counseling. Students can also attend online wellness events through the company’s mental health-and-wellness app.
The Series A funds will be used to scale the company’s growth and platform.
A recent survey found that more than 60% of students met the criteria for one or more mental health problems in 2020 and 2021, a nearly 50% increase from 2013.
In 2020, Uwill garnered a $3.25 million investment led by rapper Darryl McDaniels of Run-DMC. A year later it completed its angel funding round of $5.2 million. The company says it has since built relationships with more than 150 colleges.
College mental health startup Uwill raises $30M | MobiHealthNews
The Boston-based company will use the investment to accelerate growth and expand its platform.
Hygieia Extends Series B Round to $22M
Hygieia, a Livonia, MI-based digital therapeutics company for insulin therapy, extended its Series B round to $22M.
The round was led by Firstime Ventures and additional investment from two unnamed strategic partners.
The company intends to use the funds to explore additional ways to bring d-Nav Technology to more insulin users, for safe, effective insulin therapy.
Led by CEO Eran Bashan, Hygieia is the developer of d-Nav, a FDA-cleared technology to autonomously adjust insulin doses directly to the patient. d-Nav’s AI-powered technology automatically interprets data and independently initiates insulin management. The d-Nav Insulin Management Program adds clinical support that helps people with type 2 diabetes adjust their insulin doses according to their body’s changing insulin needs.
The company is building a national network of diabetes care centers driven by the d-Nav Technology. Hygieia’s d-Nav Clinical Partnership Program for endocrinology practices treating patients with type 2 diabetes is now in Michigan, Texas, Arizona, and North Carolina, with more states available soon. The program fits into endocrinology practice operations to improve patient outcomes while providing an added revenue stream.
Hygieia Extends Series B Round to $22M
Hygieia, a Livonia, MI-based digital therapeutics company for insulin therapy, extended its Series B round to $22M
Billing platform Inbox Health raises $22.5M and more digital health fundings
Patient billing and communications platform Inbox Health has completed its $22.5 million Series B financing round, bringing its total raise to more than $43 million.
Ten Coves Capital led the round with participation from existing investors Vertical Venture Partners, CT Innovations, Healthy Ventures, Commerce Ventures and Fairview Capital.
Steven Piaker, managing partner at Ten Coves Capital, will join Inbox Health’s board of directors.
The company offers an AI-enabled tool that automates billing and payments. The technology was designed to give patients additional insights into their charges. Patients can pay their medical bills via text, email or paper and receive support for billing questions via text, email and live chat.
Billing platform Inbox Health raises $22.5M and more digital health fundings | MobiHealthNews
Diabetes management company Hygieia extended its Series B round, and Autonomize AI, a workflow platform for healthcare and life sciences, also announced funding.
DarioHealth prices $14.3M offering
DarioHealth announced today that it priced a private placement of convertible preferred stock at $14.3 million.
New York-based DarioHealth is a leader in personalized health management, empowering people to navigate their health journeys with data-driven solutions.
DarioHealth received significant participation in the pricing by select members of leadership, the board and existing investors. The company also refinanced its existing credit facility. As a result, the company reports a proforma cash balance as of the end of the first quarter at a total of $60 million.
According to a news release, the digital therapeutic developer believes these maneuvers extend its cash runway through late 2025. DarioHealth expects the private placement to close on or before today, May 3, 2023.
https://www.massdevice.com/dariohealth-prices-14-3m-offering/?mc_cid=76f26b1663&mc_eid=df5e82ed1dGenemod Raises $4.5M in Seed Funding
Genemod, a Seattle, WA-based provider of cloud-based workspace collaboration software for biopharma R&D teams, raised $4.5M in Seed funding.
The round was co-led by defy.vc and LDV Partners, with participation from Dolby Family Ventures and Vulcan/Cercano Ventures.
The company intends to use the funds to accelerate medicine discovery, development, and market access.
Led by CEO Jacob Lee and Jin Choe, Genemod is building a dynamic cloud-based research platform designed for research teams to house their entire R&D lifecycle: from data acquisition and project documentation to inventory management and reporting. The interface allows users to visualize their data and track progress and updates including what changes are made by whom.
Genemod Raises $4.5M in Seed Funding
Genemod, a Seattle, WA-based provider of cloud-based workspace collaboration software for biopharma R&D teams, raised $4.5M in Seed funding
Autonomize AI Raises $4M in Seed Funding
Autonomize AI, an Austin, TX-based artificial intelligence (AI) company for healthcare and life sciences, raised $4M in Seed funding.
The round was led by Asset Management Ventures, with participation from ATX Venture Partners, Loop Ventures and The Next Practices Group.
The company intends to use the funds to boost its R&D and commercialization efforts.
Led by CEO and Founder Ganesh Padmanabhan, Autonomize AI specializes in AI solutions for healthcare and life-sciences organizations. Its platform uses large language models to analyze and interpret unstructured data, with evidence and explainability, and offers key generative AI capabilities to summarize and visualize information in a clear and concise manner.
Autonomize AI Raises $4M in Seed Funding
Autonomize AI, an Austin, TX-based artificial intelligence (AI) company for healthcare and life sciences, raised $4M in Seed funding
Pluto Biosciences Raises $3.7M in Seed Funding
Pluto Biosciences, a Denver, CO-based life sciences software-as-a-service (SaaS) platform, closed a $3.7m seed funding round.
The round was led by Silverton Partners.
The company intends to use the funds to further build out the product and go-to-market teams, and develop advanced product features.
Led by Rani Powers, PhD, CEO and Founder, Pluto provides a platform that gives scientific teams both a unified home for managing their biological data, and an interactive canvas for analyzing and visualizing complex biological data sets using no-code computational biology pipelines. Scientists currently use the system to accelerate biological applications spanning from preclinical and translational science research, to cell and gene therapies, drug discovery and development, and clinical research. Built to be flexible for the wide range of experiments a scientific team can perform, the platform can be used to analyze data from popular next-generation sequencing-based assays such as RNA-seq, ChIP-seq, CUT&RUN, and CRISPR screens, as well as data from other workhorse assays for pharma and biotech including metabolomics, proteomics, biochemical assays, and animal behavioral studies. The platform also integrates with sequencing services, electronic lab notebooks, project management platforms, and other collaboration tools.
